Titre:
  • Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
Auteur:Piccart-Gebhart, Martine; Pritchard, Kathleen; McCullough, Ann A.E.; Dolci, Stella; McFadden, Eleanor; Holmes, Andrew A.P.; Tonghua, Liu; Eidtmann, Holger; Dinh, Phuong; Di Cosimo, Serena; Harbeck, Nadia; Holmes, Eileen; Tjulandin, Sergei; Im, Young Hyuck; Huang, Chiun Sheng; Diéras, Véronique; Hillman, David D.W.; Wolff, Antonio C; Jackisch, Christian; Lang, Istvan; Untch, Michael; Smith, Ian; Baselga, José; Boyle, Frances; Xu, Binghe; Gomez, Henry; Suter, Thomas; Gelber, Richard R.D.; Perez, Edith A; de Azambuja, Evandro; Dueck, Amylou A.C.; Viale, Giuseppe; Zujewski, Jo Anne; Goldhirsch, Aron; Armour, Alison
Informations sur la publication:Journal of clinical oncology, 34, 10, page (1034-1042)
Statut de publication:Publié, 2016-04
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2015.62.1797
info:scp/84963612956